BALAXI PHARMACEUTICALS LIMITED — PPTs, 07-06-2025: Investor Presentation

1. Financial Highlights:

Balaxi Pharmaceuticals posted 21% consolidated revenue growth led by strong demand in African and Latin American markets. Gross margins stayed robust despite inflation and rising employee costs, reflecting solid pricing power. EBITDA and PAT improved on operational execution. The product portfolio expanded to 915 medicines across seven countries. The Hyderabad pharma formulation plant is nearing commissioning, expected to boost cost efficiencies and product quality.

2. Strategic Initiatives & Growth Drivers:

Shifting from an “asset light” to “asset right” model, Balaxi is launching its first manufacturing facility for oral solid dosage forms, aiming for supply chain backward integration. Growth plans focus on deeper market penetration in Latin America and Africa, plus entry into new regions like Southeast Asia and CIS. Expansion into institutional and tender sales channels and adoption of digital procurement, regulatory, and CRM tools are set to fuel scaling.

3. Business Developments:

The company added 85 new product registrations in the year, broadening its portfolio. Its presence spans seven countries with 38 warehouses and owned logistics, enhancing distribution. The Hyderabad plant is in final validation, expected operational soon, enabling launch of higher-margin products and speedier market access.

4. Market Position & Competitive Advantage:

Balaxi leads branded generics in Africa and is rapidly growing in Latin America. Its competitive edge lies in local regulatory expertise, a broad and expanding product portfolio, strong on-ground networks with Indian expatriates, and an asset-right supply chain that drives quality and cost leadership across semi-regulated and frontier markets.

5. Investor Implications:

The company’s move toward backward integration, consistent top-line growth, and expanded product pipeline signal positive growth potential. The new manufacturing facility is expected to enhance margins and supply control. Execution risks around plant ramp-up and geographic expansion merit attention but overall position Balaxi well to benefit from rising demand in frontier pharma markets.